Education
About Us
Working with TipRanks
Follow Us
Novo Nordisk (DE:NOVA)
FRANKFURT:NOVA
NOVA Stock Chart & Stats
Day’s Range― - ―
52-Week Range€51.00 - €136.00
Previous CloseN/A
Volume1.40K
Average Volume (3M)1.99K
Market Cap
$258.99B
Enterprise Value€2.22T
Total Cash (Recent Filing)$41.55B
Total Debt (Recent Filing)kr118.72B
Price to Earnings (P/E)19.2
Beta0.46
Next Earnings
Aug 06, 2025EPS Estimate
0.78Last Dividend Ex-Date
Mar 31, 2025Dividend Yield3.11%
Share Statistics
EPS (TTM)0.85
Shares Outstanding3,390,128,000
10 Day Avg. Volume3,149
30 Day Avg. Volume1,991
Financial Highlights & Ratios
PEG Ratio5.49
Price to Book (P/B)15.35
Price to Sales (P/S)0.00
P/FCF Ratio28.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$80.94Price Target Upside41.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Novo Nordisk News
Bulls Say, Bears Say
Bulls Say
Product InnovationNovo Nordisk is pushing ahead with high-dose oral semaglutide for the treatment of obesity as an option for patients who may not want to use injectables.
Regulatory ApprovalsNovo sees an opportunity to regain a competitive foothold with the upcoming approval/launch of CagriSema.
Bears Say
Competitive PressuresCompetitive pressures from Lilly, headwinds from compounders, and a modest benefit from its exclusive deal with select Caremark formularies leave Novo's incretin franchise in a more challenged position.
Leadership ChallengesAnnounced departure of Novo CEO highlights ongoing competitive pressures that have challenged shares of late.
Market CompetitivenessNovo Nordisk shares are expected to remain less competitive versus other peers in the cardiometabolic market.
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
1.40%
Mutual Funds
4.71% Other Institutional Investors
93.80% Public Companies and Individual Investors
NOVA FAQ
What was Novo Nordisk’s price range in the past 12 months?
Novo Nordisk lowest stock price was €51.00 and its highest was €136.00 in the past 12 months.
What is Novo Nordisk’s market cap?
Novo Nordisk’s market cap is $258.99B.
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s upcoming earnings report date is Aug 06, 2025 which is in 40 days.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on May 07, 2025. The company reported €0.85 earnings per share for the quarter, beating the consensus estimate of €0.782 by €0.068.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Undervalued.
Does Novo Nordisk pay dividends?
Novo Nordisk pays a Semiannually dividend of €0.993 which represents an annual dividend yield of 3.11%. See more information on Novo Nordisk dividends here
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is 0.78.
How many shares outstanding does Novo Nordisk have?
Novo Nordisk has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of €0.85 in its last earnings report, beating expectations of €0.782. Following the earnings report the stock price went up 1.724%.
Which hedge fund is a major shareholder of Novo Nordisk?
Currently, no hedge funds are holding shares in DE:NOVA
Novo Nordisk Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$80.94 (41.01% Upside)
$80.94 (41.01% Upside)
Blogger Sentiment
Bullish
DE:NOVA Sentiment 85%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.50%
12-Months-Change
Fundamentals
Return on Equity
87.53%
Trailing 12-Months
Asset Growth
63.64%
Trailing 12-Months
Company Description
Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
NOVA Company Deck
NOVA Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong sales and profit growth, increased patient reach, and significant regulatory milestones. However, challenges with compounded GLP-1 drugs in the U.S., increased carbon emissions, and a reduced full-year outlook due to lower-than-planned penetration of branded GLP-1 treatments were notable lowlights.Read More>NOVA Stock 12 Month Forecast
Average Price Target
€80.94
▲(41.01%Upside)